Fgf and MAPK signaling are required for localization of Rock2a and MRLC activation. (A-F2) Fgfr or MAPKK inhibition with SU5402 or PD0325901, respectively, from 28-30 hpf in claudinB:EGFP zebrafish embryos. Lower panels show sagittal view of leading pLLp region (left, EGFP; right, Rock2a). Post-treatment, Rock2a (A-C) and pMRLC (D-F) were assayed by immunolabeling. Yellow arrowheads indicate the caudal-most apical accumulation of Rock2a. Note that Rock2a is not localized to apical ends of cells in the leading region following treatments. pMRLC staining shows failure of leading-region MRLC activation following treatments. (G) Quantification of the leading region (performed as in Fig. 2H). Rock2a (n=6 embryos; P<0.03, ANOVA) and pMRLC (n=6 embryos; P<0.003, ANOVA) are not apically localized. Note there are fewer leading cells with apically localized Rock2a in Fgf-inhibited (39.9±1.1%) and MAPKK-inhibited (42.5±1.4%) embryos compared with the control (26.4±1.5%). For pMRLC staining: DMSO, 28.0±0.7%; SU5402, 34.4±0.6%; and PD0325901, 39.8±1.0%. Scale bar: 20 μm.
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ Development